BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioSavita Appoints James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer


9/27/2012 8:19:42 AM

PLYMOUTH, MI--(Marketwire - September 27, 2012) - BioSavita, Inc. announced today that its board has appointed James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer. He plans to lead the company's growth through development of its portfolio of biosimilar products and additional corporate partners for its Twin Cassette® yeast expression technology, which allows rapid production of fully functional antibodies in secreted form.

Dr. Kuo has over 20 years of life science industry experience as a venture capitalist, pharmaceutical business development executive and senior manager of private and publicly-traded biotech companies. Prior to joining BioSavita, Dr. Kuo served as Chairman and Chief Executive Officer of Adeona Pharmaceuticals, a publicly-traded Michigan biotech company. Prior to Adeona, he served as Chairman and Chief Executive Officer of BioMicro Systems, a genomic tools company. Dr. Kuo is also a founder and served as Chief Executive Officer of Discovery Laboratories, a publicly-traded company commercializing surfactant-based respiratory therapeutics. He has been Associate Director of Licensing and Development at Pfizer and Vice President of Business Development at Myriad Genetics. Dr. Kuo was Managing Director of Venture Analysis at HealthCare Ventures, a venture capital firm with $378 million in funds under management. He is Chairman of the Board at MSK Pharma, a company developing pharmaceutical therapies for pain and musculoskeletal diseases. He is also Chairman of the Board at Monarch Labs, a company commercializing medical devices for wound care. Dr. Kuo received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the Wharton School of Business. He received his B.A. in molecular biology from Haverford College.

"On behalf of the board of directors, I welcome Jim's appointment as Chairman and Chief Executive Officer," stated Joseph DeAngelo, BioSavita's board director. "His past experience shows that he can inject more commercial focus to our biosimilar pipeline and establish more partnerships for our high-throughput yeast expression cassette technology."

"It is a pleasure to join a company that is seeking to develop a portfolio of biosimilars, which potentially offers a more rapid regulatory pathway to commercial approval. I am excited that BioSavita has already established five corporate collaborations to validate its Twin Cassette® yeast expression technology," stated Dr. Kuo.

About BioSavita, Inc.

BioSavita (formerly known as ApoLife) is focused on rapidly bringing new biosimilar medicines to patients in partnership with biopharmaceutical companies. The company has developed proprietary genetically engineered strains of Saccharomyces cerevisiae yeast and Twin Cassette™ yeast expression platform technology. BioSavita's high throughput synthetic DNA technology enables the manufacture of fully functional antibodies (glycosylated and aglycosylated), single domain antibodies, fusion proteins in secreted form. For further information, please visit the company's website at www.biosavita.com.


James Kuo
Email Contact



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES